Treatment regimens may compromise gut-microbiome-derived signatures for liver cirrhosis.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33657385.
- Also identified by DOI 10.1016/j.cmet.2021.02.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Many of the gut-microbiome-derived signatures for liver cirrhosis, especially the important ones, were likely under the influence of proton pump inhibitors (PPIs). Wu et al. suggest that drug usage is a confounding factor in metagenomics analysis that should be controlled for.
Medical subject headings
- Gastrointestinal Microbiome